Ciphergen s Q4 Projections and Stock Drop; Rich Blames Core Facilities, Says Delay a Pause

Jan 09, 2004

Premium

Amid the New Year’s lull, Ciphergen Biosystems announced last Friday that its revenues for the quarter would fall short of previous forecasts, due to delays in orders.

The company said its revenues for the quarter will be in the range of $15.0 to $15.5 million, as compared to prior expectations of about $19 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Testing Less Likely

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three for Immunotherapy

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

This Week in Genome Research

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.